Mounjaro approval creates a US brand term that means one thing here and another abroad

The Food and Drug Administration approved Mounjaro (tirzepatide) injection on May 13, 2022, for use in adults with type 2 diabetes mellitus. The approval letter for New Drug Application 215866, addressed to Eli Lilly and Company, states the drug is cleared "as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus" ^[1]. FDA records list this as a Type 1 New Molecular Entity approval that received priority review ^[2].

The original approval covered a range of injectable strengths, from 2.5 mg/0.5 mL up to 60 mg/2.4 mL, across single-dose and KwikPen autoinjector formats ^[2]. FDA did not require an advisory committee review because, according to the approval letter, "outside expertise was not necessary" ^[1].

As a condition of approval, Lilly agreed to run a 15-year medullary thyroid carcinoma registry study to track any change in the annual incidence of that cancer in the United States tied to tirzepatide's introduction, with interim reports due every March through 2039 and a final report due in June 2040 ^[1]. The company also committed to a lactation study measuring tirzepatide levels in breast milk, originally scheduled for completion by July 2024 ^[1]. A pediatric study in patients ages 10 to 17 was deferred, with completion targeted for December 2027 and a final report due in September 2028 ^[1].

FDA's database shows the Mounjaro application has been amended repeatedly since 2022. Supplemental filings recorded in the agency's tracking system include labeling and packaging updates through 2023 and 2024, an "Efficacy-New Patient Population" supplement dated December 19, 2025, and both an "Efficacy-New Indication" and an "Efficacy-New Dosing Regimen" supplement dated August 27, 2026 ^[2]. The source material reviewed for this article does not describe what those later indication and population changes specifically added to the label.

Why it matters for patients

What the FDA record makes clear is that, at the moment of the original May 2022 approval, Mounjaro's US-approved use was limited to glycemic control in adults with type 2 diabetes, described in the agency's own approval letter as an adjunct to diet and exercise ^[1]. Nothing in that approval letter or in Drugs@FDA's original 2022 listing mentions weight management as an approved use ^[1][2].

That matters because the same brand name has, according to the development described here, been used for weight-management marketing outside the United States, which means Americans searching online for "Mounjaro weight loss" can end up reading material describing a use or regulatory status that does not match the FDA-approved label. The FDA documents provided for this article do not describe any non-US regulatory action, so that part of the picture is not established by the sources here — it is not yet known, from this material, exactly what other countries have authorized under the Mounjaro name or when. What is documented is the narrower fact: the original US approval, effective May 13, 2022, was for type 2 diabetes only ^[1].

Patients trying to sort out what Mounjaro is approved for in the United States can look at the FDA's own approval letter and product listing, which describe the diabetes indication and list every approved dose form, rather than relying on search results that may reflect content written for other markets ^[1][2].

What happens next

Lilly's required thyroid carcinoma monitoring study is scheduled to report interim results every March through 2039, with a final report due in June 2040 ^[1]. The pediatric study in patients ages 10–17 is slated for completion in December 2027, with a final report due by September 2028 ^[1]. FDA's own tracking system shows additional label supplements, including ones dated as recently as August 27, 2026, indicating the agency continues to review changes to how Mounjaro can be prescribed and dosed ^[2].